COR · CIK 0001140859
What Cencora, Inc. told the SEC could break it.
Cencora's dominant exposure is customer concentration: its top ten customers were about 66% of fiscal 2025 revenue, and just two — Walgreens/Boots at roughly 25% and Evernorth at about 13% — together accounted for 38%, so the loss of either relationship would materially dent revenue. As a national pharmaceutical distributor, it also continues to carry opioid-litigation exposure tied to the 2021 national Distributor Settlement, recording $60.7 million of related charges in fiscal 2025 (down from $227 million the prior year). A smaller, recurring drag comes from abroad: its International Healthcare Solutions segment absorbs roughly $50 million a year in hyperinflationary accounting effects from its Turkey operations.
3 self-disclosed vulnerabilities, pulled from its own filings, each in the company’s words, with the source. This is the risk register almost nobody reads.
In its own words
What could break it.
Customer concentration
- top 10 customers (including WBA, Evernorth) represent 66% of revenue; two named customers together are 38%high
Cencora's top 10 customers account for ~66% of revenue in FY2025; Walgreens/Boots at ~25% and Evernorth at ~13% together constitute 38% of revenue, creating significant concentration risk if either relationship is terminated.
“Our top 10 customers, including governmental agencies and group purchasing organizations ("GPO"), represented approximately 66% of revenue in fiscal 2025. In fiscal 2025, Walgreens and Boots together accounted for approximately 25% of revenue and Evernorth Health Services accounted for approximately 13% of revenue. The loss of any key customer or GPO relationship could adversely affect future revenue and results of operations.”
SEC filing →As of 2025
Litigation
- opioid litigation — ongoing charges ($60.7M in FY2025, $227M in FY2024)medium
Cencora continues to incur opioid-related litigation charges — $60.7M in FY2025 and $227M in FY2024 — reflecting an ongoing exposure as a national pharmaceutical distributor that was party to the 2021 national opioid Distributor Settlement Agreement.
“Litigation and opioid-related credit (60,671) (227,070)”
SEC filing →As of 2025
Geographic concentration
- Turkey hyperinflationary impact — ~$50M annual drag on International Healthcare Solutionslow
Cencora's International Healthcare Solutions segment records ~$49-54M annually in Turkey hyperinflationary accounting impacts, a consistent headwind from its Turkey-based operations.
“Turkey highly inflationary impact (49,571) (54,087)”
SEC filing →As of 2025
The hidden graph
Who it depends on, and who depends on it.
Relationships surfaced from filings, including ones disclosed by the other side, which is how the non-obvious ones come to light.
Its customers
Evernorth Health Services (Cigna)
“In fiscal 2025, Walgreens and Boots together accounted for approximately 25% of revenue and Evernorth Health Services accounted for approximately 13% of revenue. The loss of any key customer or GPO relationship could adversely affect future revenue and results of operations.”
Cited →“In fiscal 2025, Walgreens and Boots together accounted for approximately 25% of revenue and Evernorth Health Services accounted for approximately 13% of revenue. The loss of any key customer or GPO relationship could adversely affect future revenue and results of operations.”
Cited →
Its suppliers
Elanco Animal Health Incorporated
“Our largest customer, an affiliate of Cencora, Inc., is a third-party veterinary distributor and represented approximately 12% of our total revenue in 2025.”
In the MyPRIA app, this is checked against the companies you actually own.
← World Watch